TIGIT and neoplasm: Anti-TIGIT antibody, so far employed in preclinical studies only in combination with anti-PD-1 antibody, showed promising results in glioblastoma animal models since an increased survival was observed and correlated with the infiltration of effector T cells in the tumor [123] (Figure 4).